Pregabalin shares gabapentin's mechanism, duloxetine and buspirone carry direct FDA anxiety approvals gabapentin lacks, and ketamine has early off-label evidence for treatment-refractory anxiety.
If you want to replace gabapentin, your options depend directly on the condition you are treating. Pregabalin shares its calcium-channel mechanism. Duloxetine and buspirone carry full Food and Drug Administration (FDA) approvals for generalized anxiety disorder (GAD), and ketamine shows early clinical trial data for treatment-resistant symptoms. Finding suitable gabapentin alternatives requires separating the drug’s approved uses from the unapproved conditions it is most often prescribed to treat.
At Mind Medicine Law, we track how evolving prescription rules and clinical evidence affect your therapeutic choices. Gabapentin has become one of the most widely dispensed medications in the United States, yet the vast majority of prescriptions are written off-label for anxiety, fibromyalgia, or unapproved pain syndromes. This guide reviews five distinct alternatives, comparing their legal classifications, dosing schedules, evidence bases, and practical costs.
You might be surprised to learn that gabapentin (sold under the brand name Neurontin) holds FDA approval for only two medical conditions. The agency first approved it in 1993 as an adjunctive therapy for partial-onset seizures in patients age 3 and older with epilepsy. Later, the FDA approved it to treat postherpetic neuralgia, which is chronic nerve pain that persists after a shingles infection in adults. In routine medical practice, prescribers write gabapentin prescriptions off-label for generalized anxiety disorder, general nerve pain, fibromyalgia, and insomnia far more frequently than for its approved indications. The FDA has never evaluated or approved gabapentin for any of these off-label conditions.
Safety warnings represent another major reason you might reconsider your prescription. On December 19, 2019,1 the FDA issued a formal drug safety communication warning that gabapentin and pregabalin (known collectively as gabapentinoids) can cause serious, life-threatening breathing problems, clinically termed respiratory depression. This risk rises sharply if you take opioid painkillers or other central nervous system (CNS) depressants, if you are age 65 or older, or if you live with underlying lung conditions like chronic obstructive pulmonary disease (COPD). The FDA review evaluated 49 cases of respiratory depression reported between 2012 and 2017. Twelve of those patients died, and all 12 had at least one of these underlying risk factors. In response, the FDA mandated new warnings on gabapentinoid labels and ordered manufacturers to study their abuse potential, especially when taken alongside opioids.
Legal and pharmacy restrictions are also shifting where you live. While gabapentin is not a federally controlled substance, at least eight states classify it as a Schedule V controlled substance as of late 2025. State lawmakers introduced these controls after public health tracking documented widespread misuse, particularly individuals taking gabapentin alongside opioids to intensify the opioid high. If you live in one of these eight states, you face mandatory identity checks, monthly refill limits, and prescription tracking database checks each time you visit the pharmacy.
When you evaluate pregabalin vs gabapentin, you are comparing close chemical relatives. Both medications belong to the gabapentinoid class. They work inside your nervous system by binding to the alpha-2-delta subunit of voltage-gated calcium channels on nerve cells. This binding action slows the influx of calcium, which reduces the release of excitatory neurotransmitters throughout the brain and spinal cord. Pregabalin (sold under the brand name Lyrica) is a federally classified Schedule V controlled substance across all 50 states, reflecting its documented potential for misuse.
Despite sharing a molecular mechanism, pregabalin carries a broader portfolio of formal FDA approvals. The FDA has cleared pregabalin to treat diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, neuropathic pain associated with spinal cord injury, and partial-onset seizures as an adjunctive therapy. According to its FDA label,2 your prescriber typically starts dosing at 150 mg per day divided across two or three doses. Based on your tolerability and symptom relief, your doctor can titrate the dose upward to a maximum of 300 mg per day within one week.
If you are seeking anxiety relief, pregabalin holds a unique international status. Regulators in the European Union and Russia have formally approved pregabalin to treat generalized anxiety disorder. In the United States, however, the FDA has never approved pregabalin for GAD. If your American prescriber recommends pregabalin for anxiety, you are taking it off-label, exactly as you would be taking gabapentin. Pregabalin offers more predictable oral absorption than gabapentin, but you still face federal Schedule V prescription controls and the same 2019 FDA respiratory warning regarding combinations with opioids or CNS depressants.
If you take gabapentin off-label for either generalized anxiety disorder or chronic pain, duloxetine (brand name Cymbalta) offers a direct, on-label path forward. Duloxetine belongs to the serotonin-norepinephrine reuptake inhibitor (SNRI) class of antidepressants. Rather than targeting calcium channels, duloxetine works by inhibiting the reabsorption of both serotonin and norepinephrine in your central nervous system, increasing the active levels of both neurotransmitters across your neural pathways.
Duloxetine carries FDA approval for generalized anxiety disorder, major depressive disorder (MDD), diabetic peripheral neuropathy, and fibromyalgia. This clinical profile makes it particularly valuable if your anxiety coexists with chronic nerve or muscular pain. Per the FDA prescribing information, a standard starting dose is 30 mg taken once daily for the first week. If you tolerate the medication well, your prescriber will typically step your dose up to a target maintenance level of 60 mg once daily.
Unlike gabapentinoids, duloxetine is not a controlled substance in any state. You will not face Schedule V pharmacy reporting or early refill restrictions when managing your prescription. Because duloxetine does not suppress respiration through the gabapentinoid mechanism, it does not carry the specific December 2019 FDA breathing warning, although your doctor must still review your complete medication list for potential drug interactions.
If you rely on gabapentin exclusively to manage daily anxiety symptoms, buspirone stands out as a targeted, non-sedating pharmaceutical option. The FDA approved buspirone on September 29, 1986,3 for the treatment of generalized anxiety disorder, initially in a 10 mg tablet strength. The agency later approved 15 mg and 30 mg strengths in 1996 to accommodate standard clinical dosing adjustments.
Buspirone works through an entirely different biological pathway than gabapentin. It functions primarily as an agonist at serotonin 5-HT1A receptors in the brain. It does not bind to voltage-gated calcium channels, it does not enhance gamma-aminobutyric acid (GABA) activity, and it does not depress the central nervous system. Because of this targeted receptor profile, buspirone carries zero federal scheduling, is not a controlled substance in any state, and is not considered habit-forming by medical authorities.
For your daily routine, buspirone avoids the physical dependence risks and state-level tracking that now complicate gabapentin refills. However, buspirone provides no relief for physical nerve pain, shingles complications, or fibromyalgia. If your prescriber originally suggested gabapentin for physical discomfort alongside nervous tension, buspirone will only address the psychological and physiological symptoms of your generalized anxiety disorder.
Hydroxyzine is a first-generation antihistamine that clinicians frequently prescribe off-label or on-label for rapid anxiety relief. If you experience intermittent spikes in panic or generalized tension and want to avoid controlled substances, your prescriber might suggest hydroxyzine as a non-habit-forming option. It works primarily by blocking histamine H1 receptors in the brain, producing mild sedation and calming physical restlessness.
The clinical evidence supporting hydroxyzine was evaluated in a 2010 Cochrane systematic review led by Guaiana, Barbui, and Cipriani (review CD006815).4 The review analyzed 5 randomized controlled trials comprising 884 participants diagnosed with generalized anxiety disorder. The researchers found that hydroxyzine demonstrated greater efficacy than placebo in reducing anxiety scores across the pooled trial data.
The same Cochrane review highlighted clear clinical boundaries. The authors noted there was insufficient evidence to directly compare hydroxyzine against established treatments like buspirone or benzodiazepines. Furthermore, because standard antidepressants possess a substantially larger and more rigorous evidence base for generalized anxiety disorder, the Cochrane authors concluded that hydroxyzine should not be recommended as a first-line treatment. If you explore hydroxyzine, expect your prescriber to position it as a secondary or as-needed tool rather than your primary daily therapy.
If standard oral medications have failed to ease your symptoms, you might wonder: is ketamine an alternative to gabapentin for anxiety? Ketamine works as an N-methyl-D-aspartate (NMDA) glutamate receptor antagonist. This mechanism differs completely from the calcium-channel binding of gabapentinoids and the monoamine reuptake inhibition of standard antidepressants. At sub-anesthetic doses, ketamine modulates glutamate neurotransmission, initiating rapid neuroplastic changes across brain circuits governing mood and fear responses. Read the full ketamine guide for how it is used in depression treatment.
Clinical researchers have gathered targeted trial evidence evaluating ketamine for primary anxiety disorders. In a 2018 randomized, placebo-controlled crossover trial published in Neuropsychopharmacology,5 Taylor and colleagues evaluated 18 adults diagnosed with social anxiety disorder. A single intravenous (IV) ketamine infusion produced greater anxiety reduction than placebo: about a third of participants responded within two weeks compared to zero on placebo, according to a standardized anxiety rating scale. In an exploratory 2020 study published in the Journal of Psychopharmacology,6 Glue and colleagues observed similar anxiolytic effects when administering ketamine to a small cohort of patients with treatment-refractory generalized anxiety disorder and social anxiety disorder who were not depressed.
Before you consider ketamine, you need to understand its legal status and out-of-pocket costs. Ketamine holds no FDA approval for any anxiety condition, meaning any anxiety protocol is strictly off-label. The drug is classified federally as a Schedule III controlled substance. Insurance rarely covers ketamine when prescribed for anxiety. If you receive intravenous or intramuscular (IM) infusions in an outpatient clinic, you will typically pay between $400 and $800 per session out of pocket. If you enroll in an at-home telehealth program using sublingual lozenges, ongoing treatment typically costs between $150 and $400 per month. See our ketamine cost guide for the full breakdown.
| Alternative | Mechanism | FDA status (US) | Controlled substance | Best for |
|---|---|---|---|---|
| Pregabalin | Alpha-2-delta calcium-channel binding (same class as gabapentin) | Approved for neuropathic pain, fibromyalgia, seizures; NOT approved for anxiety in the US | Schedule V (federal) | Nerve pain needing more predictable dosing |
| Duloxetine | SNRI — blocks serotonin and norepinephrine reuptake | Approved for GAD, MDD, diabetic neuropathy, fibromyalgia | Not controlled | Anxiety that coexists with chronic pain |
| Buspirone | Serotonin 5-HT1A receptor agonist | Approved for GAD (1986) | Not controlled | Anxiety-only, non-habit-forming daily use |
| Hydroxyzine | Antihistamine (H1 receptor antagonist) | Not FDA-approved specifically for GAD; Cochrane-reviewed evidence vs placebo | Not controlled | As-needed, short-term anxiety spikes |
| Ketamine (off-label) | NMDA glutamate receptor antagonist | No approval for any anxiety disorder | Schedule III | Treatment-refractory anxiety, self-pay |
The alternative medications reviewed here do not fit every medical history or every clinical scenario. First, if you are tracking psychedelic medicine and hoping that psilocybin or 3,4-methylenedioxymethamphetamine (MDMA) can immediately replace your gabapentin, the current clinical data does not support that step. As of 2026, neither psilocybin nor MDMA has meaningful, FDA-reviewed clinical trial evidence specifically for generalized anxiety disorder or chronic neuropathic pain. Their strongest clinical research is concentrated in major depression, post-traumatic stress disorder (PTSD), and end-of-life psychological distress. You should not expect psilocybin or MDMA to act as a ready substitute for your gabapentin prescription today.
Second, you must never stop taking gabapentin or pregabalin abruptly. If you take either medication on a regular daily schedule, sudden discontinuation can trigger a severe withdrawal syndrome. Documented withdrawal symptoms include acute rebound anxiety, severe insomnia, profuse sweating, nausea, and, in rare instances, life-threatening seizures. You should never attempt to transition to an alternative medication on your own. Any switch requires a structured, gradual taper managed directly under your prescriber’s supervision.
The rankings and assessments presented here reflect federal regulations, state statutes, and published clinical trials available as of 2026. Several concrete regulatory or scientific shifts would alter our evaluation of these treatment paths. If the FDA approved pregabalin for generalized anxiety disorder in the United States, aligning American indications with European Union approvals, pregabalin would immediately become the primary on-label gabapentinoid for anxiety care.
Similarly, if academic researchers conduct large-scale, multi-center randomized controlled trials evaluating ketamine against active comparators for generalized anxiety disorder, ketamine’s clinical standing would change. Right now, small sample sizes like the 18 adults in the 2018 Taylor trial limit ketamine to an exploratory, off-label option. Expanded federal scheduling changes, such as the Drug Enforcement Administration classifying gabapentin federally as Schedule V, would also alter the administrative burden across all 50 states.
Your next step should focus on matching your specific symptoms, medical history, and state regulations to the right medical protocol. If you want to review your options before speaking with your prescriber, use our depression and anxiety treatment path tool to evaluate potential gabapentin alternatives.
Get psychedelic research & policy updates
New trials, FDA decisions, and legal changes for psychedelic — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.